Join the Skin Cancer group to help and get support from people like you.
Skin Cancer News (Page 3)
Related terms: Cancer, Skin
Melanoma Can Strike Black Americans, Often With Deadlier Results
TUESDAY, May 14, 2024 – Melanoma, while rare among Black Americans, is often detected later with devastating consequences, a new study finds. Black people are frequently diagnosed with melanoma at...
Outdoor Workers Face Skin Cancer Danger
FRIDAY, May 10, 2024 – Steve Murray, 68, has spent a lot of time out in the sun, at work and at play. Murray worked construction for several decades, and as a child spent summers on the beach in...
FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma
September 28, 2018 – The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous...
FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic...
Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations
BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy...
FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
March 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic...
Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis
Leverkusen, Germany, May 11, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the U.S. Food and Drug Administration (FDA) has g...
FDA Approves Yervoy to Reduce the Risk of Melanoma Returning after Surgery
October 28, 2015 – Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to...
FDA Approves Imlygic (talimogene laherparepvec) for the Treatment of Melanoma
October 27, 2015 – The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in...
FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma
July 24, 2015 – The U.S. Food and Drug Administration today approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation...
FDA Approves Keytruda (pembrolizumab) for Advanced Melanoma
September 4, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no...
FDA Approves Tafinlar (dabrafenib) for Advanced Melanoma
May 29, 2013 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib). Tafinlar is indicated as a single-agent oral treatment for...
FDA Approves Mekinist (trametinib) for Advanced Melanoma
May 29, 2013 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist (trametinib) as a single-agent oral treatment for unresectable or metastatic...
FDA Approves Zelboraf and Companion Diagnostic Test for Late-Stage Skin Cancer
Second melanoma drug approved this year that improves overall survival August 17, 2011 - The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with...
Further information
Related condition support groups
Basal Cell Carcinoma, Melanoma, Cancer